APA (7th ed.) Citation

Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., . . . Schlumberger, M. J. (2014). Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet, 384(9940), 319. https://doi.org/10.1016/S0140-6736(14)60421-9

Chicago Style (17th ed.) Citation

Brose, Marcia S., et al. "Sorafenib in Radioactive Iodine-refractory, Locally Advanced or Metastatic Differentiated Thyroid Cancer: A Randomised, Double-blind, Phase 3 Trial." Lancet 384, no. 9940 (2014): 319. https://doi.org/10.1016/S0140-6736(14)60421-9.

MLA (9th ed.) Citation

Brose, Marcia S., et al. "Sorafenib in Radioactive Iodine-refractory, Locally Advanced or Metastatic Differentiated Thyroid Cancer: A Randomised, Double-blind, Phase 3 Trial." Lancet, vol. 384, no. 9940, 2014, p. 319, https://doi.org/10.1016/S0140-6736(14)60421-9.